| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lucid Diagnostics Inc.$1
+0.01 (+0.99%)
F 9Pipeline Score MedTech · Commercial
Market Cap
217.28 M
EPS
-0.47
P/E Ratio
-
Value Trade
834.23 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.26 M
R&D Expenses
1.21 M
Operating CF
-12.10 M
Total Assets
34.08 M
Total Liabilities
30.08 M
Equity
4.00 M
D/E Ratio
12,345
5.94 %
Week
-17.05 %
1 Month
-21.9 %
3 Month
5.42 %
6 Month
-91.61 %
5 Year
-91.61 %
All Time
Cash Data
Cash Position
27.88 M
Monthly Burn
4.03 M
Runway
5.2 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
822.60 K
52 Week Range
0.90 - 1.70
% held by Insiders
21.22 %
% held by Institutions
18.17 %
Enterprise Value
226.34 M
Total Shares
195.18 M
Short %
4.64 %
Float Shares
150.48 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 6%
Micro Cap (rank 857 of 911)
Percentile RankLucid Diagnostics Inc. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EsoGuard | Barrett's esophagus | — | 2025-12-09 | technical success rate: 95%; cell collection time: under two minutes; patient population: 11,991 Read More | Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Read More | |
EsoGuard | Barrett's esophagus | — | 2025-12-09 | technical success rate: 95%; cell collection time: under two minutes; patient population: 11,991 Read More | Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Read More | |
EsoGuard | Barrett's esophagus | — | 2025-12-09 | technical success rate: 95%; cell collection time: under two minutes; patient population: 11,991 Read More | Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LUCD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LUCD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LUCDLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Processed 3,177 EsoGuard tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and
Lucid Diagnostics Inc. provided a business update and reported its first quarter 2026 financial results, processing 3,177 EsoGuard tests and generating $1.3 million in revenue. The company holds $45 million in proforma cash, allowing for extended operations into 2027. The chairman expressed strong confidence in achieving Medicare coverage, which remains a crucial milestone for the company. However, Lucid reported substantial operating expenses and net losses during the quarter.
Read more →LUCDLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics Inc. will hold a business update conference call on May 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the first quarter 2026 financial results. The call will be accessible via webcast and telephone.
Read more →LUCDLucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics has successfully closed an underwritten offering of 18 million common shares, raising approximately $18 million. The offering was supported by a significant investment from an institutional investor. The funds will be utilized for working capital and general corporate purposes, as the company continues to focus on cancer prevention diagnostics.
Read more →LUCD▼ -16.8%on this newsshared move
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics has announced a registered direct offering of 18 million common shares at $1.00 each, aiming to raise about $18 million. The offering is backed by a $15 million investment from a fundamental institutional investor. Proceeds will be used for working capital and general corporate purposes, with the closing expected on April 24, 2026.
Read more →LUCDLucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. CEO Lishan Aklog will lead the discussion, which will be available for live streaming and archived for later viewing. The company specializes in cancer prevention diagnostics, particularly for patients at risk of esophageal cancer.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Lucid Diagnostics provided a business update and reported its financial results for Q4 and full year 2025, highlighting a revenue of $1.5 million. The company expanded access to its EsoGuard test through a contract with the U.S. Department of Veterans Affairs and presented positive data on esophageal precancer detection. Future priorities include deepening relationships with health systems and securing Medicare coverage.
Read more →LUCDLucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
Lucid Diagnostics Inc. will hold a business update conference call on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations and fourth quarter 2025 financial results. The event will be accessible via webcast and telephone for investors.
Read more →LUCD▼ -6.6%on this news
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
Lucid Diagnostics has secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This contract will enhance access to esophageal precancer testing for over nine million veterans annually. The agreement allows VA facilities to procure EsoGuard at Medicare rates, reflecting confidence in the test's clinical evidence.
Read more →LUCDLucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics has announced positive data from the largest real-world study on esophageal precancer detection, involving nearly 12,000 patients. The study highlights the effectiveness of the EsoGuard Esophageal DNA Test and EsoCheck device, showcasing a 95% technical success rate and rapid cell collection. The findings support the tools' utility in non-invasive screening for Barrett's esophagus.
Read more →LUCDLucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics has been named a top-ranking honoree in the GenomeWeb 2025 Best Places to Work program, recognized for its positive workplace culture and commitment to employee development. The company, which specializes in cancer prevention diagnostics, emphasizes a culture of collaboration and service to patients. This accolade reflects the dedication of Lucid's team to uphold high standards in their work.
Read more →LUCDLucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York City. CFO Dennis McGrath will be available for one-on-one investor meetings. Lucid focuses on cancer prevention through its EsoGuard® Esophageal DNA Test, aimed at patients at risk of esophageal precancer.
Read more →LUCD▲ +6.7%on this newsshared move
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics reported a positive business update for Q3 2025, processing 2,841 EsoGuard tests and generating $1.2 million in revenue. The company ended the quarter with over $47 million in cash, extending its financial runway through 2026. A recent Medicare advisory committee meeting yielded unanimous support for EsoGuard coverage, bolstering the company's commercialization efforts.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics Inc. will hold a business update conference call on November 12, 2025, at 8:30 AM ET. CEO Lishan Aklog will provide insights into the company's operations and growth strategy, while CFO Dennis McGrath will discuss the third quarter financial results. The call will be accessible via telephone and webcast.
Read more →LUCD▲ +5.9%on this news
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 in New York City. CFO Dennis McGrath will host one-on-one meetings with investors during the event. The company focuses on cancer prevention, particularly for patients at risk of esophageal cancer due to gastroesophageal reflux disease (GERD).
Read more →LUCDLucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Lucid Diagnostics has appointed John R. Palumbo to its Board of Directors, effective September 22, 2025. With 40 years of experience in healthcare, Palumbo's leadership is expected to guide the company through significant growth phases. His prior roles include senior positions at major healthcare organizations, and he aims to help Lucid address critical needs in cancer prevention.
Read more →LUCDLucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Lucid Diagnostics has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs. Her role will focus on enhancing market access for the EsoGuard test, particularly in securing Medicare coverage. The company is optimistic about expanding patient access and commercial coverage, bolstered by positive feedback from a recent MolDX CAC meeting.
Read more →LUCDLucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics has successfully closed its public offering of 28.75 million shares at $1.00 per share, raising around $26.9 million. The funds will be used for working capital and general corporate purposes. The offering was managed by Canaccord Genuity LLC and BTIG, LLC, with a prospectus supplement filed with the SEC.
Read more →LUCD▼ -19.7%on this newsshared move
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics has announced the pricing of its public offering of 25 million shares at $1.00 each, aiming to raise approximately $25 million. The offering includes an option for underwriters to purchase an additional 3.75 million shares. Proceeds will be used for working capital and corporate purposes, with the offering expected to close on September 11, 2025.
Read more →LUCDLucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced its intention to conduct a public offering of common stock to raise capital for working activities and corporate purposes. The company, which focuses on cancer prevention through diagnostics for patients at risk of esophageal issues, is engaging underwriters for this offering and has laid out conditions dependent on market conditions. This move signals potential growth for the company, despite uncertainties surrounding completion and market acceptance of its products.
Read more →LUCDLucid Diagnostics to Host Investor Call on Monday, September 8, 2025
Lucid Diagnostics Inc. has announced an investor call scheduled for September 8, 2025, at 8:30 AM ET, where they will discuss the outcomes of the MolDX Contractor Advisory Committee meeting held on September 4. This meeting relates to the reconsideration of Local Coverage Determination for their EsoGuard® Esophageal DNA Test, which is designed for the detection of upper gastrointestinal conditions. The call will provide insights into the company's strategies and future directions concerning its cancer prevention initiatives.
Read more →LUCD▲ +6.8%on this news
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
Lucid Diagnostics Inc. has announced that its Chairman and CEO, Lishan Aklog, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference 2025. The event is scheduled for September 5, 2025, in New York, NY. This participation signifies the company's focus on early detection methods in cancer prevention. The conference will allow Lucid to interact with investors and discuss its innovative diagnostic products, particularly for patients at risk of esophageal cancer.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results Processed 2,756 EsoGuard tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma ca
Lucid Diagnostics provided a business update and reported its financial results for the second quarter of 2025, highlighting revenue of $1.2 million from 2,756 EsoGuard tests processed. The company emphasized its strengthened financial position, aided by over $30 million in proforma cash, as it prepares for significant reimbursement milestones. A major focus is the upcoming Multi-Jurisdictional Contractor Advisory Committee meeting regarding Medicare coverage for EsoGuard, which is anticipated to support the test’s clinical utility. Despite a reported net loss, improvements were noted compared to previous years, setting a hopeful tone for future commercialization efforts.
Read more →LUCDLucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics Inc. has announced its participation in several upcoming investor conferences, including the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference and the Canaccord Genuity 45th Annual Growth Conference. Management will engage in 1x1 meetings and a fireside chat during these events to discuss the company's cancer prevention diagnostic solutions. The EsoGuard® Esophageal DNA Test, aimed at patients with GERD, represents a significant innovation in early cancer detection. This involvement in investor conferences could potentially boost market interest in Lucid's offerings.
Read more →LUCD▼ -6.5%on this news
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics Inc. has announced a scheduled business update conference call and webcast set for August 13, 2025. The call will be led by Lishan Aklog, M.D., the company's Chairman and CEO, and will include an overview of the company's operations and growth strategy. Additionally, CFO Dennis McGrath will present the financial results for the second quarter of 2025, providing insights into the company's performance.
Read more →LUCD▼ -6.8%on this news
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics
Lucid Diagnostics Inc. announced a virtual MolDX Contractor Advisory Committee (CAC) meeting scheduled for September 4, 2025, regarding Local Coverage Determination L39256 for its EsoGuard Esophageal DNA Test. The meeting aims to discuss the clinical literature and gather insights from medical experts, a step viewed as significant progress in securing Medicare coverage for the test. Lucid's CEO expressed optimism stemming from the consensus within the GI community on the test’s clinical benefits, backed by professional guidelines and substantial patient data. The public can attend the meeting, though there will be no audience questions.
Read more →LUCDMajor California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics
Lucid Diagnostics has announced a partnership with Hoag, a prominent healthcare system, to implement a comprehensive esophageal precancer testing initiative. This program utilizes the EsoGuard Esophageal DNA Test to enhance screening capabilities across Hoag's vast healthcare network, aiming to identify patients at risk of developing esophageal cancer. The collaboration is viewed as a crucial step toward addressing the rising incidence of esophageal cancer and improving early detection through a rapid, non-invasive testing method. Leaders from both organizations express optimism about the potential life-saving impact of the program.
Read more →LUCDLucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
Lucid Diagnostics Inc. will be added to the Russell 2000 and Russell 3000 indexes, effective June 27, 2025. This inclusion reflects the company's positive growth and progress in enhancing shareholder value. The presence in these indexes could improve Lucid's visibility to institutional investors and is a significant milestone for the company. However, the announcement includes forward-looking statements that highlight potential risks and uncertainties affecting future operations.
Read more →LUCD▲ +7.6%on this news
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results Processed 3,034 EsoGuard tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upc
Lucid Diagnostics (Nasdaq: LUCD) has reported its financial results for the first quarter of 2025, processing 3,034 EsoGuard tests and generating revenue of $0.8 million. The company has successfully secured significant capital, with over $40 million in proforma cash, which extends its operational runway beyond critical reimbursement milestones. While Lucid is making strides in its cash-pay and insurance programs for EsoGuard, it also faces challenges, as reflected by a reported net loss of $26.9 million for the quarter. The company remains focused on leveraging its diagnostics to prevent esophageal cancer in at-risk patients.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Lucid Diagnostics Inc. has announced a business update conference call scheduled for May 14, 2025, at 8:30 AM ET. The call will feature presentations from CEO Lishan Aklog and CFO Dennis McGrath, who will discuss the company’s operations and first quarter financial results. Lucid is focused on preventing cancer through early detection in patients at risk of esophageal precancer and cancer, emphasizing its EsoGuard Esophageal DNA test. The conference call will be accessible via teleconference and webcast.
Read more →LUCDNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics
Lucid Diagnostics announced positive results from an NCI-sponsored study of its EsoGuard Esophageal DNA Test, which effectively detects esophageal precancer in asymptomatic patients. The study, showing an unprecedented negative predictive value of 100%, supports its use in a broader target population as recommended by AGA guidelines. This promising data may significantly expand the market for EsoGuard, with projections indicating a potential increase of up to 70%. Ongoing clinical evaluations are backed by an $8 million grant from the NIH.
Read more →LUCDLucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025. CEO Lishan Aklog will be featured in a fireside chat that will be webcast live, with a replay available for 30 days. The conference will also include one-on-one meetings between company management and investors. Lucid is known for its cancer prevention diagnostics targeting esophageal health, offering innovative tools for early detection of precancerous conditions.
Read more →LUCDLucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck
Lucid Diagnostics has launched the "Embrace the Future" campaign to promote its EsoCheck device, coinciding with Esophageal Cancer Awareness Month. The campaign will be highlighted at the upcoming Digestive Disease Week conference in May 2025. EsoCheck has shown impressive results with a safety record and a 99% negative predictive value in detecting esophageal precancer. Lucid aims to bring awareness to the importance of early detection and prevention in esophageal cancer, which affects thousands of Americans annually.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard rev
Lucid Diagnostics reported a positive business update with significant advancements in the adoption of its EsoGuard tests. In the fourth quarter of 2024, the company processed a record 4,042 tests, representing a notable 45% increase sequentially and 84% year-over-year. Their revenue reached $1.2 million in Q4 2024, supported by new insurance coverage and cash-pay contracts. Despite a total net loss of $45.5 million for the year, Lucid's leadership is optimistic about capitalizing on new sales channels and broader payor coverage in 2025.
Read more →LUCDLucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics has reported a significant update to the National Comprehensive Cancer Network (NCCN) Guidelines, which now include recommendations for esophageal precancer screening. The updated guidelines endorse non-endoscopic biomarker testing, particularly Lucid's EsoGuard Esophageal DNA Test, as a worthy alternative to invasive procedures. This is expected to improve insurance policy coverage for esophageal precancer testing and enhance patient access to early detection measures, thereby potentially preventing esophageal cancer. Lucid continues to focus on cancer prevention efforts targeting at-risk populations, particularly those with gastroesophageal reflux disease.
Read more →LUCDLucid Diagnostics
Lucid Diagnostics has announced that their EsoGuard Esophageal DNA Test has demonstrated significant clinical utility in a recent study. The study, published in Gastroenterology & Hepatology, shows that using EsoGuard can elevate the diagnostic yield of confirmatory upper endoscopy for Barrett's Esophagus among at-risk patients. These findings support EsoGuard's cost-effectiveness and its role in enhancing compliance with screening recommendations. The study adds to Lucid's growing body of clinical evidence and could facilitate improved insurance coverage for the test.
Read more →LUCDLucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics has secured its first positive commercial insurance coverage policy for its EsoGuard® Esophageal DNA Test from Highmark Blue Cross Blue Shield in New York. This policy will cover non-invasive screening for esophageal precancer and cancer in eligible patients, marking a significant advancement for Lucid in the cancer prevention diagnostics space. The CEO expressed optimism that this landmark decision could influence other insurers to follow suit, thereby enhancing access to important precancer testing. Lucid is dedicated to expanding the reach of its innovative testing solutions to better serve at-risk patients.
Read more →LUCD▼ -14.4%on this newsshared move
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Lucid Diagnostics Inc. will hold a business update conference call and webcast on March 24, 2025, at 8:30 AM ET. The CEO, Lishan Aklog, will provide a business overview, while CFO Dennis McGrath will discuss the financial results for the fourth quarter of 2024. This event is part of their ongoing strategy to communicate business operations and growth to stakeholders.
Read more →LUCDLucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Lucid Diagnostics, a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced the closure of a registered direct offering that raised approximately $15.3 million. The offering involved selling nearly 14 million shares of common stock at a price of $1.10 per share. The company plans to utilize the net proceeds for working capital and other corporate purposes, reinforcing its commitment to preventing esophageal cancer through early detection solutions.
Read more →LUCDLucid Diagnostics Announces $15.3 Million Registered Direct Offering
Lucid Diagnostics Inc. has announced a registered direct offering to sell 13,939,331 shares of common stock, totaling approximately $15.3 million in gross proceeds. The purchase price is set at $1.10 per share, with the offering expected to close on or about March 5, 2025. The company intends to allocate the net proceeds towards working capital and general corporate purposes. Lucid Diagnostics specializes in cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD).
Read more →LUCD▲ +5.3%on this newsshared move
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics
Lucid Diagnostics Inc. has announced an $8 million NIH grant awarded to a consortium of medical centers for a five-year study aimed at improving esophageal precancer detection. The study will utilize Lucid's EsoCheck and EsoGuard technologies among patients who are at risk for Barrett's Esophagus but do not exhibit symptoms of chronic GERD. This initiative could help in identifying previously under-screened populations and potentially reduce the high mortality rates associated with esophageal cancer. The principal investigators, supported by Lucid, highlight the importance of enhancing screening protocols for at-risk individuals.
Read more →LUCDLucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lucid Diagnostics Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, allowing its stock to continue trading on the Nasdaq Capital Market. The company had previously failed to meet the requirement but achieved compliance by maintaining the necessary closing bid price of $1.00 per share for ten consecutive trading days. This compliance enhances the company's market credibility and supports its ongoing business operations in cancer prevention diagnostics.
Read more →LUCD▼ -6.3%on this newsshared move
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Lucid Diagnostics has signed its first concierge medicine contract with LEAA Health, allowing its members to access EsoGuard, an esophageal precancer detection test. This partnership aims to enhance personalized care services and drive revenue through the growing demand for preventive healthcare. Lucid is focused on securing Medicare and commercial coverage for its innovative testing solutions, further enhancing their reach in the market. The US concierge medicine sector is projected to reach $10.9 billion by 2032, indicating substantial growth opportunities for Lucid's offerings.
Read more →LUCDLucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Lucid Diagnostics Inc. announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 11-12, 2025. President and COO Shaun O'Neil will host one-on-one meetings during the event to connect with investors. The company focuses on early detection of esophageal precancer and cancer through innovative diagnostic tools. However, the press release also notes various risks and uncertainties that could impact Lucid's future operations.
Read more →LUCDLucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Lucid Diagnostics has announced a record quarterly volume of EsoGuard Esophageal DNA tests, reaching over 4,000 tests performed in Q4 2024. This figure marks a 45% sequential increase compared to Q3 2024 and an 84% year-over-year growth from Q4 2023. The company's CEO expressed optimism for 2025, citing strategic initiatives to convert test volume into revenue. The full results for the quarter will be disclosed in mid-March 2025.
Read more →LUCDLucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Lucid Diagnostics Inc. has received a 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement. This extension allows the company until June 16, 2025, to meet the necessary conditions without immediate impact on shares trading. The company plans to actively monitor and improve its share prices during this period to regain compliance.
Read more →LUCDLucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
Lucid Diagnostics has partnered with VITALExam to enhance access to its EsoGuard Esophageal DNA Test specifically for firefighters, who face a heightened risk of esophageal cancer. This collaboration commenced with a testing event in Tuscaloosa, Alabama, under a broader initiative to drive EsoGuard revenue. The partnership seeks to provide early cancer detection and comprehensive health care for first responders, aligning with both organizations' missions to protect firefighter health. The EsoGuard test represents an innovative tool aimed at preventing cancer deaths through early screening.
Read more →LUCDProspective Clinical Utility Study of Lucid Diagnostics
Lucid Diagnostics has announced that its CLinical Utility of EsoGuard (CLUE) study has been accepted for publication, highlighting significant findings regarding its EsoGuard esophageal precancer testing. The study reported an 85% patient compliance rate for referrals to endoscopy following the non-invasive test, indicative of the test's reliability and effectiveness in clinical settings. Over 99% of negative EsoGuard patients were not referred for endoscopy, emphasizing the test's accuracy. This data strengthens the case for EsoGuard as a critical tool for esophageal cancer prevention.
Read more →LUCDLucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
Lucid Diagnostics has successfully completed a refinancing of its convertible debt, raising approximately $18 million in net cash. This refinancing, which involved issuing new convertible notes to long-term equity shareholders, enhances the company's balance sheet and extends its financial runway beyond critical reimbursement milestones. The net proceeds position Lucid with about $33 million in cash, reinforcing shareholder confidence in its cancer prevention technology. The company aims to leverage this funding for ongoing development and commercialization efforts in its diagnostic offerings.
Read more →LUCDLucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Lucid Diagnostics has submitted a clinical evidence package to the MolDX program, seeking Medicare coverage for its EsoGuard Esophageal DNA Test. This effort is aimed at re-evaluating the current local coverage determination, which presently restricts access to its innovative early detection technology. The submission includes data from multiple peer-reviewed studies that advocate for EsoGuard's effectiveness in identifying precancerous conditions. Lucid's CEO emphasized the submission as a critical milestone for the company as it strives to enhance accessibility of its testing to at-risk Medicare beneficiaries.
Read more →LUCDLucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024. The company's management aims to highlight its innovations in cancer prevention, particularly its EsoGuard® Esophageal DNA Test. This product addresses the needs of patients with gastroesophageal reflux disease (GERD) at risk of esophageal cancer. Webcasts of the event will be available on the company's investor relations website.
Read more →LUCD▲ +5%on this newsshared move
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results EsoGuard revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initi
Lucid Diagnostics Inc. reported a business update and financial results for Q3 2024, highlighting a 20% sequential increase in EsoGuard revenue. The company has completed the clinical evidence package for Medicare coverage submission and expanded its direct contracting initiatives to support revenue growth. Despite these advancements, Lucid continues to face financial losses, with a net loss reported at $12.4 million for the quarter. The emphasis on enhancing patient access to its crucial diagnostic technologies remains a key focus for the company going forward.
Read more →LUCDLucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
Lucid Diagnostics Inc. is expanding its direct contracting initiative to drive revenue for its EsoGuard Esophageal DNA Test through fully-contracted programs like #CheckYourFoodTube Testing Events, Concierge Medicine, and Employer Markets. The company has bolstered its commercial team with seasoned professionals from GRAIL to enhance these efforts. With recent successes at events like the one with Fort Worth Fire Department and positive indicators in concierge markets, Lucid aims to convert its growing test volume into guaranteed revenue while navigating potential regulatory and market challenges ahead.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
Lucid Diagnostics Inc. has announced a business update conference call and webcast scheduled for November 13, 2024. The call will be led by CEO Lishan Aklog, who will provide insights into the company’s operations and growth strategy, while CFO Dennis McGrath will discuss the third quarter financial results. Lucid is committed to advancing cancer prevention technologies, particularly through their proprietary EsoGuard® test aimed at early detection of esophageal cancer in at-risk patients.
Read more →LUCDLucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Lucid Diagnostics has received a Notice of Allowance for a patent from the USPTO, which covers a proprietary method utilizing methylation of the CCNA1 gene to detect esophageal precancer and cancer. This patent enhances Lucid's intellectual property portfolio and supports the continued development of their EsoGuard Esophageal DNA Test. The test, which assesses DNA methylation through a noninvasive procedure, aims to address the early detection of esophageal conditions in patients at risk, particularly those suffering from gastroesophageal reflux disease. This development underscores the innovative approach Lucid is taking in cancer prevention diagnostics.
Read more →LUCDLucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
Lucid Diagnostics Inc. is set to participate in the 2024 Maxim Healthcare Virtual Summit on October 15, 2024. The event will feature a fireside chat with Dennis McGrath, Lucid's CFO, highlighting the company's innovative approach to cancer prevention. Lucid specializes in early detection tools for patients at risk of esophageal cancer, emphasizing its commitment to noninvasive screening methods. A recording of the discussion will be available afterward on the company's investor relations website.
Read more →LUCDLucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
Lucid Diagnostics Inc. is set to participate in The MedTech Conference 2024, scheduled for October 15-17 in Toronto, Canada. The company will feature its EsoCheck® and EsoGuard® technologies at the Innovation Pavilion, aimed at early detection of esophageal cancer. Lucid's CEO, Lishan Aklog, will also take part in a CEOs Unplugged event, enhancing the company's visibility and networking opportunities at this leading industry gathering. The MedTech Conference is recognized as a significant venue for medical technology advancements, attracting numerous participants worldwide.
Read more →LUCDLucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
Lucid Diagnostics conducted its inaugural #CheckYourFoodTube Precancer Testing Event in Cincinnati, targeting former NFL players to raise awareness about the risks of esophageal cancer due to GERD. The event featured educational sessions and on-site EsoGuard testing, emphasizing early detection's importance. Lucid aims to expand these initiatives to other cities, highlighting collaboration among former players to promote health awareness. The EsoGuard test represents a significant advancement in cancer prevention for at-risk populations.
Read more →LUCDAmerican Foregut Society
Lucid Diagnostics Inc. announced the endorsement of its EsoGuard Esophageal DNA Test by the American Foregut Society (AFS) during the 2024 AFS Annual Meeting. The event, taking place from September 26-28, 2024, will feature a session led by Dr. Dan Lister discussing the benefits of EsoGuard as a non-invasive screening method for Barrett's Esophagus. The AFS emphasizes the importance of early detection to prevent esophageal cancer and advocates for coverage of EsoGuard by medical payors. Lucid's CEO expressed gratitude for the support from the AFS and its leaders, reinforcing the company's role in cancer prevention through innovation.
Read more →LUCDLucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Lucid Diagnostics Inc. announced its participation as the sole Diamond Sponsor at the upcoming ISDE World Congress, emphasizing their EsoGuard® Esophageal DNA Test for early detection of esophageal precancer. The company will host a symposium featuring leading experts in esophageal diseases, aiming to enhance awareness and collaboration in cancer prevention. The congress will address various aspects of esophageal disease management, providing a valuable platform for knowledge exchange. Despite the positive developments, the company acknowledges potential risks related to market acceptance and regulatory approval of its products.
Read more →LUCDLucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Lucid Diagnostics has entered into a memorandum of understanding with Front Line Mobile Health to enhance the early detection of esophageal cancer among at-risk firefighters. This collaboration will focus on co-marketing initiatives to promote Lucid's EsoGuard Esophageal DNA test. The partnership aims to expand patient access to this innovative screening tool and is a continuation of their prior efforts in health awareness among first responders. Both companies are committed to leveraging each other's resources to provide crucial health testing services to firefighters, who are at a higher risk of developing esophageal cancer.
Read more →LUCDLucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Lucid Diagnostics has published an analytical validation study of its EsoGuard Esophageal DNA test in the journal Diagnostics. The study confirms the assay's strong analytical performance, reporting high sensitivity, specificity, and accuracy. EsoGuard, along with the EsoCheck device for non-invasive sample collection, aims to enhance early detection of esophageal precancer and cancer in at-risk patients. The results further substantiate the clinical utility and validity of the assay, contributing to Lucid's mission in cancer prevention.
Read more →LUCDThe American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
Lucid Diagnostics Inc. announced that the American Foregut Society has formally requested health insurance providers to cover the EsoGuard Esophageal DNA test. This is aimed at improving early detection of esophageal precancer to prevent mortality from esophageal cancer. The open letter emphasizes scientific backing for the test and its role in reducing health disparities in screening accessibility. Lucid's leadership reinforced their commitment to making the EsoGuard test widely available to at-risk patients through expanded insurance coverage.
Read more →LUCD▲ +6.3%on this newsshared move
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results EsoGuard test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad
Lucid Diagnostics provided a business update and financial results for Q2 2024, highlighting a significant increase in EsoGuard test volume, which rose 31% compared to the previous quarter and 44% annually. The company showed optimistic progress in its clinical data positioning for easier reimbursement and broader coverage. Additionally, Lucid has executed 50 high-volume precancer testing events, including some with contracted upfront payments, as part of its strategic growth efforts in cancer prevention diagnostics.
Read more →LUCDLucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Lucid Diagnostics announced a successful #CheckYourFoodTube Precancer Testing Event in Fort Worth, Texas, in partnership with the Fort Worth Fire Department and Front Line Mobile Health. Approximately 200 firefighters deemed at risk for esophageal precancer underwent testing using Lucid's EsoGuard® Esophageal DNA test. The event underscores the importance of early detection of esophageal cancer, particularly for firefighters who face increased risks. Lucid anticipates potentially increased revenue through similar collaborations with self-insured entities and medical care providers.
Read more →LUCDLucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics (LUCD) announced positive findings from its ENVET-BE clinical utility study, confirming the effectiveness of its EsoGuard Esophageal DNA test. The study showed that EsoGuard serves as a non-invasive triage tool, increasing the positive yield of endoscopies for esophageal precancer detection by 2.4 times compared to traditional methods. With significant implications for early diagnosis and treatment, the findings position EsoGuard as a vital resource in esophageal cancer screening protocols.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Lucid Diagnostics Inc. has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The call will feature insights from Lucid's CEO, Dr. Lishan Aklog, regarding the company's operations and growth strategies, as well as a discussion of the second quarter 2024 financial results by CFO Dennis McGrath. This event will be available via the company's investor relations website, demonstrating Lucid's commitment to keeping stakeholders informed.
Read more →LUCDLucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Inc. has launched a newly redesigned corporate website aimed at enhancing accessibility to information regarding its cancer prevention technologies. The revamped site, as stated by VP Jenna Mowatt, is designed to provide a user-friendly experience for patients, healthcare professionals, and investors. The company focuses on preventing esophageal cancer through innovative diagnostics, including their EsoGuard® test, aimed at improving early detection for at-risk patients. Lucid Diagnostics is a commercial-stage subsidiary of PAVmed Inc.
Read more →LUCDLucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Lucid Diagnostics announced positive findings from its ESOGUARD BE-1 study, validating the performance of the EsoGuard® Esophageal DNA test for detecting esophageal precancer in a screening population. The study noted a sensitivity of 87.5% and a negative predictive value of 98.6%, reinforcing the test's reliability alongside previous studies. Supported by clinical evidence from multiple centers and a peer-reviewed Cleveland VA screening study, Lucid aims to push for Medicare reimbursement and enhance routine esophageal cancer screenings. The findings mark a significant step forward in early detection strategies for at-risk patients.
Read more →LUCD4,000th Firefighter Undergoes Lucid Diagnostics
Lucid Diagnostics has reached a significant milestone, with the 4,000th firefighter undergoing esophageal precancer testing through the EsoGuard test during a #CheckYourFoodTube event. This initiative, organized in collaboration with Mass General Brigham and Boston Firefighters Local 718, aims to address the heightened cancer risk faced by firefighters. The success of this testing event coincides with Esophageal Cancer Awareness Month, underscoring the importance of early detection and preventative measures in this at-risk community. Despite the positive developments, the company faces industry-related risks and uncertainties that could affect its market performance.
Read more →LUCDLucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results Quarterly EsoGuard test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred
Lucid Diagnostics reported a successful first quarter of 2024, with EsoGuard test volume rising by 10% and revenue reaching $1.0 million. The company completed a $29.8 million Series B Preferred Stock offering to strengthen its financial position. A pre-submission meeting for Medicare coverage is scheduled for July 2024, following positive clinical validation of the EsoGuard test. Despite these advancements, Lucid reported high operating expenses and a sizable net loss.
Read more →LUCDLegacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
Lucid Diagnostics announced a Class II FDA recall of the legacy EsophaCap sponge-on-a-string device due to serious failures reported in recent studies. The company emphasized that their current EsoCheck device, which uses advanced technology for cell collection, remains unaffected and is the preferred method for esophageal precancer detection. Notably, the recall was driven by serious device failures that led to required interventions. Lucid proactively informed the FDA about the issues, indicating their commitment to patient safety.
Read more →LUCDLucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors Final closing yields total gross proceeds of $29.8 million from offering Mr.
Lucid Diagnostics Inc. has successfully closed its Series B / B-1 Preferred Stock offering, yielding a total of $29.8 million in gross proceeds. The offering, led by loyal institutional investors, provides the company with crucial working capital as it approaches significant reimbursement milestones. Additionally, Lucid appointed Dennis Matheis to its Board of Directors, bringing over thirty years of healthcare experience to the team, which could enhance the company's operational strategies moving forward.
Read more →LUCD▲ +8.1%on this newsshared move
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing EsoGuard demons
Lucid Diagnostics announced a peer-reviewed publication detailing positive results from a clinical validation study of its EsoGuard Esophageal DNA Test. Funded by the National Cancer Institute, the study showcased EsoGuard's 89% sensitivity in detecting early precancer stages, surpassing traditional diagnostic methods. The research supports Lucid's goals for securing commercial and Medicare coverage, with findings published in the American Journal of Gastroenterology. This significant clinical data is a pivotal advancement for esophageal cancer prevention strategies.
Read more →LUCD▲ +8.1%on this newsshared move
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics Inc. will conduct a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. CEO Lishan Aklog will provide insights into the company’s operations and growth strategy, while CFO Dennis McGrath will deliver the first quarter financial results. The event underscores Lucid's commitment to transparency and communication with stakeholders regarding its cancer diagnostic initiatives.
Read more →LUCD▲ +9.9%on this news· ran to +39% by day 3shared move
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
Lucid Diagnostics Inc. has partnered with the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month. The initiative highlights the link between acid reflux and esophageal cancer, emphasizing the importance of early detection. This collaboration includes public service announcements displayed in Times Square to encourage at-risk individuals to get tested. Lucid Diagnostics aims to improve patient access to its EsoGuard test for early precancer detection, further supporting advocacy efforts in esophageal cancer education.
Read more →LUCDLucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. will have its President & COO Shaun O'Neil participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. This event aims to enhance the company's visibility in the healthcare sector and facilitate investor engagement through scheduled one-on-one meetings. The company's focus on cancer prevention through its EsoGuard® test underscores its commitment to addressing serious health concerns related to gastroesophageal reflux disease.
Read more →LUCDLucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Lucid Diagnostics Inc. reported a business update along with its preliminary financial results for the fourth quarter and the full year 2023. The company saw a significant increase in EsoGuard revenue, attributed to stable test volumes and improving revenue cycle management. Lucid is working to expand its clinical validity data to secure medical policy coverage, including exploring Medicare coverage. The company also discussed its direct contracting initiatives, which are anticipated to contribute positively to revenue in upcoming quarters.
Read more →LUCDLucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Lucid Diagnostics announced positive results from a prospective clinical validation study of its EsoGuard esophageal precancer test. The study showed a sensitivity of 92.9% and a negative predictive value of 98.6%, establishing EsoGuard as a powerful screening tool for early detection of esophageal cancer. This study is the first to validate the test in a screening population and supports its clinical utility in guiding physician referrals for further testing. The findings contribute to the growing body of evidence advocating for broader use of EsoGuard in preventive healthcare.
Read more →LUCDLucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Lucid Diagnostics Inc. has announced that it will present four abstracts, including research on its EsoGuard® Esophageal DNA Test, at the upcoming Digestive Disease Week (DDW) 2024 Conference. The presentations, scheduled for May 18 to 24 in Washington, D.C., will showcase studies on esophageal precancer detection and a new genetic classifier. Both Lucid and its collaborators from Case Western Reserve University will be involved in these presentations. This marks a significant opportunity for Lucid to demonstrate its advancements in cancer prevention technology.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Lucid Diagnostics Inc. has announced that it will hold a business update conference call and webcast on March 26, 2024, at 8:30 AM ET. The call will feature CEO Lishan Aklog discussing the company's operations and growth strategy, while CFO Dennis McGrath will provide an overview of the financial results for the fourth quarter and full year of 2023. The event underscores Lucid's commitment to transparency and engagement with investors.
Read more →LUCDLucid Diagnostics Provides Update Regarding World Trade Center Health Program
Lucid Diagnostics announced an update regarding the World Trade Center Health Program, noting that the EsoGuard® Esophageal DNA test had been incorrectly listed as a covered benefit due to a clerical error. The company has been directed to engage with Clinical Centers of Excellence to rectify the situation. Despite this setback, Lucid remains dedicated to providing cancer prevention testing for first responders, having tested thousands through their programs. The company aims to ensure access to essential esophageal precancer testing for high-risk groups.
Read more →LUCDLucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Lucid Diagnostics CEO Lishan Aklog emphasized the advantages of the EsoCheck esophageal cell collection device during his congressional testimony. Dr. Aklog pointed out that EsoCheck provides a gentler and more targeted alternative to older technologies, significantly improving patient experience and detection accuracy. Additionally, he noted that the device has facilitated high-volume testing with successful results reported from numerous events. With promising milestones achieved since its FDA clearance, Lucid is focusing on addressing the cancer risks associated with gastroesophageal reflux disease.
Read more →LUCDLucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
Lucid Diagnostics has announced a contract with the World Trade Center Health Program to provide EsoGuard® Esophageal DNA testing as a covered benefit for over 120,000 participants, including 9/11 responders and survivors. The test, which costs $2,475.81, will aid in the early detection of esophageal precancer among individuals at increased risk of cancer due to their exposure to hazardous materials during the attacks. This effort reflects Lucid's commitment to cancer prevention and enhancing patient access to critical diagnostic services.
Read more →LUCDLucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Lucid Diagnostics Inc. announced the publication of three peer-reviewed studies demonstrating the clinical utility of its EsoGuard esophageal DNA test for detecting esophageal precancer. The studies, which collectively include data from over 1,000 patients, show high concordance between EsoGuard results and physicians' decisions for upper endoscopy referrals. This evidence aims to enhance market access initiatives and support medical policies regarding EsoGuard's coverage. Plans for additional publications on expanded registry cohorts are forthcoming, reflecting ongoing research in this domain.
Read more →LUCDLucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
Lucid Diagnostics has announced the expansion of its executive team with the appointment of Natalie Carfora as Vice President of Market Access and James Fricchione as Vice President of Employer Markets. Shaun M. O'Neil has been promoted to President and COO, emphasizing a coordinated effort to secure payor coverage and direct contracts. These changes aim to support the company's growth in translating test volume into revenue, particularly for its EsoGuard esophageal DNA test in the cancer prevention market. The leadership team brings extensive industry experience that could strengthen Lucid's market position.
Read more →LUCDLucid Diagnostics Provides Business Update and Third Quarter Financial Results Quarterly EsoGuard test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be
Lucid Diagnostics Inc. reported a significant increase in third-quarter financial results, with EsoGuard test volume up 17% and revenue soaring 392% sequentially. The company highlighted the importance of its upgraded revenue cycle management system, which has sustained revenue growth. Additionally, it emphasized the expansion of its clinical utility data supporting payer coverage, culminating in a solid foundation for future growth. Despite the positive revenue trends, Lucid faced notable financial challenges, including a GAAP net loss of approximately $14.2 million.
Read more →LUCDLucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
Lucid Diagnostics (LUCD) has launched the next-generation EsoGuard® Esophageal DNA test, known as EsoGuard 2.0, which enhances assay performance and reduces costs. This new version has been validated for detecting esophageal precancer and cancer with improved sensitivity and specificity. Additionally, Lucid will hold an Investor Day on December 13, 2023, in New York City to discuss the new test and overall company progress. The launch is seen as a significant milestone following rigorous research and development processes.
Read more →LUCDLucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Lucid Diagnostics Inc. will have its CEO, Dr. Lishan Aklog, present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will spotlight the company's commitment to cancer prevention, particularly regarding esophageal precancer. Management will also be available for one-on-one meetings with interested investors, emphasizing their proactive engagement in the medical diagnostics space. Lucid focuses on addressing the needs of patients at risk of developing cancer due to gastroesophageal reflux disease.
Read more →LUCDLucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
Lucid Diagnostics has announced the establishment of two clinical registries, PREVENT and PREVENT-FF, aimed at collecting real-world data on the effectiveness of the EsoGuard Esophageal DNA testing. The registries will evaluate the clinical utility and validity of the test in at-risk populations, including firefighters. Initial results from these registries indicate a strong concordance between test results and physician decision-making, with a technical success rate exceeding 99%. The data gathered will contribute to ongoing research efforts and may enhance Lucid's commercial strategy.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
Lucid Diagnostics announced a business update conference call scheduled for November 14, 2023, at 8:30 AM EST. During this call, CEO Lishan Aklog will discuss the company's operations and growth strategy. CFO Dennis McGrath will present the financial results for the third quarter of 2023. The event reflects the company's commitment to transparency and stakeholder communication in the cancer prevention space.
Read more →LUCDPAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City. The panel presentation is scheduled for September 27, 2023, and will feature Dr. Lishan Aklog and Dennis McGrath, highlighting their work in medical technology and cancer prevention. Lucid Diagnostics is recognized for its EsoGuard and EsoCheck tools, aimed at early detection of esophageal precancer.
Read more →LUCDLucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
Lucid Diagnostics has announced positive interim data from the Clinical Utility of EsoGuard study, demonstrating that its Esophageal DNA testing shows excellent concordance with medical decision-making by physicians. The study's findings indicate that 100% of EsoGuard-positive patients were appropriately referred for confirmatory endoscopy, while 99% of negative patients were not. These results support the real-world clinical utility of EsoGuard in identifying at-risk patients for esophageal precancer. The company plans to expand the study and release further data on a larger cohort in the future.
Read more →LUCD▲ +5.9%on this newsshared move
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
Lucid Diagnostics has released positive results from a study demonstrating the clinical utility of its EsoGuard Esophageal DNA test for early detection of esophageal precancer in firefighters. The study showed a perfect concordance between test results and physician referrals, providing strong evidence for the test's effectiveness. These findings align with legislation aiming to ensure firefighters have access to early detection cancer tests. Lucid aims to leverage this data to engage payors for coverage of the EsoGuard test.
Read more →LUCDLucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
Lucid Diagnostics has entered into its first direct employer contract with Ancira Auto Group to provide EsoGuard esophageal precancer testing as part of the company's health and wellness program. This initiative aims to enhance cancer prevention among Ancira's employees across twelve locations in South Texas. Through this three-year agreement, eligible employees will receive testing and appropriate follow-up based on the results. The partnership reflects Lucid's commitment to expanding access to early detection testing in innovative ways.
Read more →LUCDLucid Diagnostics Provides Business Update and Second Quarter Financial Results
Lucid Diagnostics provided a significant business update along with its financial results for the second quarter of 2023. The company reported a 20% sequential increase and a dramatic 159% annual increase in EsoGuard test volume. Upgrades to the revenue cycle management are already yielding positive results, improving claims processing and payments. The company also highlighted groundbreaking cancer detection results from an NCI-funded study, achieving 100% detection of esophageal cancers and over 80% of precancers. Despite these advancements, Lucid reported a net loss of $11.4 million for the quarter.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
Lucid Diagnostics Inc. has announced a business update conference call and webcast scheduled for August 15, 2023. During this event, CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the financial results for the second quarter of 2023. The call emphasizes Lucid's commitment to cancer prevention and early detection in patients at risk of esophageal issues. Interested parties can access the call via a dedicated phone line or through the company’s website.
Read more →LUCDLucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Lucid Diagnostics Inc. has announced that its Executive Vice President & COO, Shaun O'Neil, will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The conference will provide an opportunity for one-on-one meetings between management and investors, indicating the company's commitment to engaging with stakeholders. Lucid Diagnostics focuses on cancer prevention through its EsoGuard esophageal DNA test, aimed at patients with GERD at risk of esophageal cancer.
Read more →LUCDLucid Diagnostics Launches First EsoGuard® Mobile Test Unit
Lucid Diagnostics has launched its first EsoGuard mobile test unit aimed at facilitating early detection of esophageal precancer in at-risk patients. The inaugural event is co-hosted by Florida Digestive Health Specialists in Sarasota, Florida, emphasizing increased access to this vital screening. This initiative is part of Lucid's commitment to combat esophageal cancer through early identification and intervention. The company aims to expand the reach of its noninvasive testing method, which is crucial given the rising incidence of esophageal cancer in the region.
Read more →LUCDLucid Diagnostics Provides Business Update and First Quarter Financial Results
Lucid Diagnostics has reported strong growth in its EsoGuard testing volume, with a 57% increase compared to the previous quarter and a remarkable 245% increase year-on-year. The company attributes this success to enhanced commercial efforts and increased awareness of its screening tools for esophageal precancer. Financial results for Q1 2023 show revenues of $0.4 million and a GAAP net loss of $16.2 million. Lucid also announced its plans to extend its cash runway following recent funding activities.
Read more →LUCDLucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
Lucid Diagnostics presented promising data for its EsoGuard and EsoCheck technologies at the Digestive Disease Week 2023 conference. Highlights include EsoGuard's excellent sensitivity in detecting esophageal precancer, even in challenging cases like Barrett's Esophagus. The EsoCheck device achieved a 98% success rate in a large cohort, reinforcing the viability of non-endoscopic testing approaches. These findings support updated guidelines advocating for non-invasive screening in populations at risk of esophageal cancer.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
Lucid Diagnostics Inc. announced it will hold a business update conference call and webcast on May 16, 2023, at 8:30 AM EST. The session will feature updates from CEO Lishan Aklog and CFO Dennis McGrath, covering the company's operations and first-quarter financial performance. This initiative signals Lucid's ongoing efforts to engage with investors and share updates about its cancer prevention technologies.
Read more →LUCD▲ +8.1%on this news
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
Lucid Diagnostics announced the publication of a foundational Local Coverage Determination (LCD) by Noridian Healthcare Solutions, which will become effective on May 28, 2023. This LCD outlines coverage criteria for molecular testing for esophageal precancer in Medicare beneficiaries, closely aligning with a previous LCD issued by the Palmetto GBA MAC's MolDX Program. Lucid aims to enhance access to its EsoGuard test, the first commercial diagnostic test for widespread screening of esophageal precancer, by submitting it for Technical Assessment under these foundational LCDs later this year.
Read more →LUCDLucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. has announced that its leadership, including Dr. Lishan Aklog and CFO Dennis McGrath, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023. The company specializes in cancer prevention and addresses risks associated with gastroesophageal reflux disease (GERD). Lucid's diagnostic product, the EsoGuard® Esophageal DNA Test, provides a critical tool for the early detection of esophageal precancer in at-risk patients. Institutional investors are encouraged to engage with management at the conference.
Read more →LUCDLucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer Foundational LCD, to be effective
Lucid Diagnostics has announced the publication of a Future Effective Medicare Local Coverage Determination (LCD) for molecular testing of esophageal precancer and cancer, effective May 14, 2023. The LCD reflects significant feedback from stakeholders, enhancing guidelines for access to tests like EsoGuard. This recognition of EsoGuard as a non-invasive screening tool is expected to improve early detection capabilities for at-risk patients. Lucid plans to submit EsoGuard for Technical Assessment based on forthcoming clinical utility data.
Read more →LUCDLucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer
Lucid Diagnostics has announced the publication of a Future Effective Local Coverage Determination (LCD) for molecular testing of esophageal precancer and cancer, effective May 14, 2023. This foundational LCD allows Lucid to submit its EsoGuard test for Technical Assessment once sufficient clinical utility data is available. The updated guidelines support non-endoscopic biomarker testing, addressing issues with the effectiveness of traditional endoscopy methods. Lucid's CEO expressed optimism regarding the alignment of the new guidelines with expert recommendations and the potential for improved patient access to critical diagnostics.
Read more →LUCDLucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results 4Q22 and projected 1Q23 EsoGuard test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually. Co
Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, reported substantial growth in EsoGuard test volumes for Q4 2022, with significant annual increases. The company has signed an agreement with MultiPlan, enhancing access to its services for approximately 60 million consumers. Despite these advancements, Lucid's revenue remains relatively low, and the company continues to face high operating expenses. The recent financing of $24.6 million is expected to extend its cash runway into 2024 as it continues to pursue commercial milestones.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023
Lucid Diagnostics Inc. has announced a business update conference call scheduled for March 14, 2023. The call will feature CEO Lishan Aklog discussing the company's operational overview and growth strategy, along with CFO Dennis McGrath covering the fourth-quarter 2022 financial results. The event underscores Lucid's commitment to transparency and innovation in cancer prevention through its EsoGuard diagnostic test for GERD patients. A replay of the call will be available for 30 days afterward on their investor relations website.
Read more →LUCDLucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event Partners with San Antonio Fire Department to test nearly 400 firefighters for esophageal precancer during Firefighter Cancer Awareness Month over t
Lucid Diagnostics partnered with the San Antonio Fire Department to conduct its first #CheckYourFoodTube Precancer Testing Event, screening nearly 400 firefighters for esophageal precancer. This initiative aims to promote cancer awareness among firefighters, especially during Firefighter Cancer Awareness Month. The on-site testing utilized Lucid's EsoCheck device and the EsoGuard DNA test, which is the only commercial diagnostic tool available for early detection. Dr. Rachelle Hamblin of the SAFD emphasized the importance of early detection in saving lives, and Lucid plans to expand similar testing events nationwide.
Read more →LUCD▲ +20%on this news
PAVmed and Lucid Diagnostics Provide Strategic Business Update Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercializat
PAVmed Inc. and its subsidiary Lucid Diagnostics have announced a strategic business update emphasizing resource reallocation towards prioritizing the commercialization of their products. As part of this shift, they will reduce their workforce by approximately 20% and streamline their product portfolio to decrease quarterly cash burn by 25%. The companies will focus intensified efforts on their flagship offerings, including the EsoGuard test, while pausing development of other products. This reorganization aims to enhance operational efficiency and drive future growth despite a challenging market environment.
Read more →LUCDLucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30
Diagnostics Provides Business Update and Quarter 2022 Financial Results test volume increased 28% sequentially and 436% annually call and webcast to be held today at 4:30 PM EDT YORK, November 14, 2022 (BUSINESS WIRE)-Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Com
Read more →LUCDLucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results EsoGuard test volume increased 60% for quarter and over 300% annually CLIA-Certified LucidDx Labs fully operational and bil
Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results test volume increased 60% for quarter and over 300% annually LucidDx Labs fully operational and billing as an independent entity call to be held today at 4:30 PM EDT YORK, August 15, 20
Read more →LUCD▼ -7.5%on this news
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results Conference call to be held today at 4:30
Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results call to be held today at 4:30 PM EDT YORK, May 11, 2022 (BUSINESS WIRE) - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company"), a commercial-stage, cancer prevention medical dia
Read more →LUCD▼ -6.7%on this newsshared move
Lucid Diagnostics' Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans Lucid's first commercial payer agreement provides in-network access and payment for its EsoGuard DNA test to over 8 mi
Diagnostics' Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans first commercial payer agreement provides in-network access and payment for its EsoGuard DNA test to over 8 million covered lives YORK, May 9, 2022 (BUSINESS WIRE)-Lucid Diagnostics
Read more →LUCDLucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination Updated American College of Gastroenterology clinical guideline supports es
Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard on samples collected with Eso
Read more →LUCD▲ +6.6%on this news
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results Conference call to be held today at 4:30
Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results call to be held today at 4:30 PM EDT YORK, March 29, 2022 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical techn
Read more →LUCDLucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results Conference call to be held today at 4:30
Diagnostics Provides Business Update and Preliminary Quarter and Full Year 2021 Financial Results call to be held today at 4:30 PM EDT YORK, March 28, 2022 (BUSINESS WIRE) - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid", the "Company") a commercial-stage, cancer prevention m
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call on
Diagnostics to Hold a Business Update Conference Call on March 28, 2022 conference call and webcast at 4:30 PM EDT YORK, March 7, 2022 (BUSINESS WIRE) - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, a majorit
Read more →LUCDPAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth New wholly owned Lucid subsidiary now performing EsoGuard Esophageal DNA Test in its own new state-of-the-art CLIA-certifie
Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth wholly owned Lucid subsidiary now performing EsoGuard Esophageal DNA Test in its own new state-of-the-art CLIA-certified, CAP-accredited clinical laboratory YORK, March 3, 2022 - (BUSINES
Read more →LUCDLucid Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference NEW YORK-(BUSINESS WIRE)-Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medi
Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference YORK-(BUSINESS WIRE)-Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc
Read more →LUCDPAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers Patients in Denver, Salt Lake City, and Las Vegas metropolitan areas now have access to a rapid, non-invasive, office-based test to detect eso
Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers in Denver, Salt Lake City, and Las Vegas metropolitan areas now have access to a rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer YORK,
Read more →LUCD▲ +8.2%on this news
Lucid Diagnostics' EsoGuard Esophageal DNA Test Wins "Diagnostics Innovation of the Year" Award BioTech Breakthrough's Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry
Diagnostics' EsoGuard Esophageal DNA Test Wins "Diagnostics Innovation of the Year" Award Breakthrough's Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry YORK, October 28, 2021 - (BUSINESS WIRE) - Lucid Diagnostics Inc. (Nasdaq:
Read more →LUCDLucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
Lucid Diagnostics Inc. announced the successful closing of its initial public offering on October 18, 2021, raising $70 million by selling 5 million shares at $14 each. The company focuses on cancer prevention, particularly for patients with gastroesophageal disease. Lucid's EsoGuard test is the first of its kind for early detection of esophageal precancer. The offering was managed by Cantor and Canaccord Genuity.
Read more →LUCDLucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Inc. has announced the pricing of its initial public offering, offering 5 million shares at $14 each, aiming to raise $70 million. The stock is set to trade on Nasdaq under the ticker LUCD starting October 14, 2021. The offering is subject to customary closing conditions and includes an option for underwriters to purchase additional shares. Lucid focuses on cancer prevention through its EsoGuard test for at-risk GERD patients.
Read more →Competitive Position
How LUCD ranks across every disease it competes inCompetitive Position is a premium feature
See how LUCD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial